Funding for this research was provided by:
Health Department of Sichuan Province (18ZD013)
Received: 16 September 2022
Accepted: 18 July 2023
First Online: 30 August 2023
<!--Emphasis Type='Bold' removed-->Declarations
: The “Umbilical Cord-derived Mesenchymal Stem Cells in Aplastic Anemia Therapy” was established according to the ethical guidelines of the Declaration of Helsinki and was approved by the Institutional Animal Care and Treatment Committee of West China Hospital on 7, February, 2018. The approval number was No. 2018261A. MSCs were isolated and collected from human placenta, with written consent of donors, which was approved by the ethical committee of Sichuan Neo-life Stem Cell Biotech Inc.on January, 2018 (No. 201801).
: Written informed consent was obtained from the patient for publication of this article and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
: Please contact the author for data and materials.
: The authors declare that there is no competing interests.